Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
128.63
-1.47 (-1.13%)
At close: Feb 20, 2026, 4:00 PM EST
128.76
+0.13 (0.10%)
After-hours: Feb 20, 2026, 6:19 PM EST
Neurocrine Biosciences Revenue
In the year 2025, Neurocrine Biosciences had annual revenue of $2.86B with 21.45% growth. Neurocrine Biosciences had revenue of $805.50M in the quarter ending December 31, 2025, with 28.33% growth.
Revenue (ttm)
$2.86B
Revenue Growth
+21.45%
P/S Ratio
4.51
Revenue / Employee
$1,430,250
Employees
2,000
Market Cap
12.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 505.20M | 21.45% |
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | 788.10M | 336.90M | 74.67% |
| Dec 31, 2018 | 451.20M | 289.57M | 179.16% |
| Dec 31, 2017 | 161.63M | 146.63M | 977.51% |
| Dec 31, 2016 | 15.00M | -4.77M | -24.12% |
| Dec 31, 2015 | 19.77M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 2.92M | -50.22M | -94.51% |
| Dec 31, 2012 | 53.14M | -24.27M | -31.36% |
| Dec 31, 2011 | 77.41M | 43.91M | 131.08% |
| Dec 31, 2010 | 33.50M | 30.55M | 1,034.47% |
| Dec 31, 2009 | 2.95M | -1.02M | -25.71% |
| Dec 31, 2008 | 3.98M | 2.75M | 224.75% |
| Dec 31, 2007 | 1.22M | -38.01M | -96.88% |
| Dec 31, 2006 | 39.23M | -84.66M | -68.33% |
| Dec 31, 2005 | 123.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Viatris | 14.12B |
| Elanco Animal Health | 4.59B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.13B |
| Amneal Pharmaceuticals | 2.93B |
| Hims & Hers Health | 2.21B |
| Lantheus Holdings | 1.53B |
NBIX News
- 7 days ago - Neurocrine Biosciences: Growth Beyond Just Ingrezza - Seeking Alpha
- 8 days ago - Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance - Benzinga
- 8 days ago - Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting - Seeking Alpha
- 9 days ago - Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 - PRNewsWire
- 25 days ago - Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - PRNewsWire
- 5 weeks ago - Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - PRNewsWire